Loading…
Employees: 992
Size Hangzhou Alltest Biotech (688606.SS) is a China Health Care company (Medical Specialties) with a market value of $521M, the 3769th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥45.91 on 6 Nov 2026.
Performance Over six months the shares fell 15.0%, against -13.9% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 0.4% over the last twelve months (peer median +5.6%); the operating margin is 13.3% (peer median 0.1%).
Valuation It trades at 7.4× forward earnings against a peer median of 24.8× (cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.8 points above its cost of capital (6.2% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥885M | CN¥902M | CN¥862M | CN¥748M | CN¥3.36B |
| Revenue growth | — | +5% | +15% | -78% | — |
| Gross profit | CN¥446M | CN¥435M | CN¥464M | CN¥352M | CN¥2.00B |
| EBITDA | n/a | CN¥223M | CN¥283M | CN¥148M | CN¥1.42B |
| Net income | CN¥113M | CN¥220M | CN¥302M | CN¥181M | CN¥1.18B |
| Free cash flow | CN¥57.9M | -CN¥9.29M | CN¥116M | -CN¥480M | CN¥1.11B |
| Capital expenditure | CN¥120M | CN¥219M | CN¥221M | CN¥533M | CN¥270M |
| Total debt | CN¥6.72M | CN¥7.41M | CN¥4.10M | CN¥23.9M | CN¥21.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688606.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.2% | -3.7% | 5th lowest of 21 |
| 6-month return | -15.0% | -13.9% | 9th lowest of 21 |
| Distance from 52-week high | -37.0% | -38.6% | 10th highest of 21 |
| Revenue growth (TTM) | +0.4% | +5.6% | 7th lowest of 21 |
| Operating margin | 13.3% | 0.1% | 7th highest of 21 |
| Forward P/E | 7.4× | 24.8× | cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -3.9% | 8.8% | 2nd least demanding of 11 |
| Growth delivered (Del g) | -4.3% | +8.8% | 3rd lowest of 11 |
| Hurdle (Req g minus delivered) | +0.5 pp | +0.3 pp | 6th least demanding of 11 |
| ROIC minus cost of capital | +0.8 pp | -9.9 pp | 4th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 7.4× | -3.9% | -4.3% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | n/a | 14.8% | -4.7% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | n/a | 10.1% | +120.2% |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | n/a | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | n/a | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 24.4× | 5.0% | +5.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 28.2× | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 25.2× | 6.3% | +24.4% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 18.5× | 19.3% | +12.4% |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 21.7× | 22.3% | +4.2% |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | n/a | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | n/a | n/a | n/a |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | n/a | 7.4% | -7.8% |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 12.2× | -5.6% | +7.7% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | n/a | n/a | n/a |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 31.8× | 6.5% | +10.0% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 59.1× | 11.5% | +11.0% |